Welcome to the Bioasis Technologies Hub On AGORACOM

Free
Message: Re: Dr. Mark Day interview with Proactive Investors at BIO CEO

narmac perhaps the logic is the Xb3 binds to fewer receptors with a much larger dose and delivers a bigger punch. 

Koo

Share
New Message
Please login to post a reply